Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Unfortunately the Vaccitech plc (NASDAQ:VACC) share price slid 50% over twelve months. That's disappointing when you consider the market returned 6.6%. Vaccitech may have better days ahead, of course; we've only looked at a one year period.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

View our latest analysis for Vaccitech

Because Vaccitech made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Vaccitech grew its revenue by 100% over the last year. That's a strong result which is better than most other loss making companies. The share price drop of 50% over twelve months would be considered disappointing by many, so you might argue the company is getting little credit for its impressive revenue growth. Prima facie, revenue growth like that should be a good thing, so it's worth checking whether losses have stabilized.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

While Vaccitech shareholders are down 50% for the year, the market itself is up 6.6%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. It's great to see a nice little 2.2% rebound in the last three months. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Vaccitech is showing 4 warning signs in our investment analysis , and 1 of those is a bit unpleasant...

But note: Vaccitech may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).